Muhammet Sait SAĞER, Kerim SÖNMEZOĞLU, Metin HALA, Pınar Çiğdem KOCAEL, Meftune ÖZHAN, Özgül EKMEKÇİOĞLU, Sabire YILMAZ AKSOY, Anar ALIYEV, Betül VATANKULU, Melih Engin ERKAN

The role of FDG PET/CT in detection of distant metastasis in theinitial staging of breast cancer

Background/aim: We aimed to evaluate the role of FDG PET/CT in the detection of extraaxillary regional nodal/distant metastasis in breast cancer patients and to assess the value of FDG PET/CT for detecting distant metastases in patient subgroups. Materials and methods: A total of 254 patients with breast cancer (248 female, 6 male) who underwent PET/CT for initial staging were enrolled. Patients were divided into four groups: Group 1 consisted of 154 patients diagnosed by tru-cut/core/FNAB, Group 2 comprised 32 patients diagnosed by excisional biopsy, Group 3 included 62 patients who had mastectomy-axillary lymph node dissection, and Group 4 consisted of 6 patients who had axillary lymph node metastasis diagnosed by excisional biopsy. Results: PET/CT detected distant metastasis in 76 of the 254 patients. Of these patients, 21.7% had bone/bone marrow metastasis, 7.1% had lung metastasis, 13% had mediastinal lymph node metastasis, 4.8% had liver metastasis, 9.8% had other organ/system metastasis, and 6% had other lymphadenopathies. According to T staging, the percentages of distant metastasis were as follows: 13.6% of the 66 T1 stage patients, 35.7% of the 129 T2 stage patients, 40% of the 20 T3 stage patients, and 33.3% of the 39 T4 stage patients. Conclusion: FDG-PET/CT led to a change in the stage of disease and the treatment approach in newly diagnosed breast cancer patients due to its superiority in detecting extraaxillary regional lymph node metastases and distant metastases.

PDF

___

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212 236.
2. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N et al. SEER Cancer Statistics Review, 19752003 (based on November 2005 SEER data submission). Bethesda, MD, USA: National Cancer Institute; 2006.
3. Fisher B. Malignancies of the breast. In: Cameron RB, editors. Practical Oncology. Norwalk, CT, USA: Appleton & Lange; 1994. pp. 417434.
4. Hossfeld DK, Sherman CD, Love RR, Bosch FX. Manual of Clinical Oncology. 5th ed. Geneva, Switzerland: UICC; 1990. pp. 236248.
5. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97: 966975.
6. Carlson RW, McCormick B. Update: NCCN breast cancer clinical practice guidelines. J Natl Compr Canc Netw 2005; 3: S7S11.
7. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2: 157164.
8. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002; 32: 3546.
9. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18: 34953502.
10. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005; 23: 16641673.
11. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-Dglucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008; 19: 12491254.
12. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, Hennequin C, Vilcoq JR, Cuvier C, Toubert ME et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008; 71: 695704.
13. Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN et al. FDGPET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 2011; 16: 11111119.
14. Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, Koretz K, Glatting G, Rieber A, Kreienberg R et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28: 351358.
15. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol I 2008; 35: 475483.
16. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005; 11: 204209.
17. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, Fontanillas M, Pons F. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26: 47464751.
18. Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging. Hell J Nucl Med 2011; 14: 135139.
19. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, Kimmig KR, Forsting M, Bockisch A, Antoch G. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008; 49: 12151222.
20. Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol I 2010; 37: 10771086.
21. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009; 50: 231238.
22. Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP. 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009; 115: 50385047.
23. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793802.
24. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T, Nishimura T. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol I 2005; 32: 12531258.
25. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500 2507.
26. Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18] fluoro-D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol 2008; 10: 6266.
27. Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004; 27: 407410.